SCHEMBL276590

SCHEMBL276590

[c]1ccc2csccc1-2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1439053 0.82 CYP2A6 (0.52)
SCHEMBL6103317 0.77 PDGFRB (0.42)
SCHEMBL17350220 0.76 CYP2A6 (0.40)
SCHEMBL3576853 0.74 CYP2A6 (0.43)
SCHEMBL196071 0.73 CYP2A6 (0.58)
SCHEMBL6653596 0.70 CYP2A6 (0.43)
SCHEMBL3459789 0.68 CYP2A6 (0.41)
SCHEMBL26516 0.67 ALDH1A1 (0.42)
SCHEMBL8096259 0.67 CYP2A6 (0.40)
SCHEMBL3778177 0.66 CYP2A6 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113272292-B (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases 雅盖隆大学 2024-04-12 CN claimed
EP-4149453-A1 COMBINATION TREATMENT OF LIVER DISORDERS Terns Pharmaceuticals, Inc. (US) 2023-03-22 EP claimed
EP-4149452-A1 COMBINATION TREATMENT OF LIVER DISORDERS Terns Pharmaceuticals, Inc. (US) 2023-03-22 EP claimed
CN-115811973-A Combination therapy for liver disorders 拓臻制药公司 2023-03-17 CN claimed
CN-115811972-A Combination therapy for liver disorders 拓臻制药公司 2023-03-17 CN claimed
US-20220073461-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) 2022-03-10 US claimed
WO-2021231644-A1 COMBINATION TREATMENT OF LIVER DISORDERS TERNS PHARMACEUTICALS, INC. (US) 2021-11-18 WO claimed
WO-2021231646-A1 COMBINATION TREATMENT OF LIVER DISORDERS TERNS PHARMACEUTICALS, INC. (US) 2021-11-18 WO claimed
EP-3908580-A1 (2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES UNIWERSYTET JAGIELLONSKI (PL) 2021-11-17 EP claimed
CN-113272292-A (2, 5-dioxopyrrolidin-1-yl) (phenyl) -acetamide derivatives and their use in the treatment of neurological diseases 雅盖隆大学 2021-08-17 CN claimed
EP-0799218-A1 DIARYL-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1997-10-08 EP claimed
EP-0783486-A1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1997-07-16 EP claimed
CN-1144526-A Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents NISSAN CHEMICAL IND LTD (JP) 1997-03-05 CN claimed
US-5593994-A ANTIINFLAMMATORY AGENTS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-01-14 US claimed
EP-0751944-A1 THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1997-01-08 EP claimed
WO-1996036623-A1 DIARYL-5-OXYGENATED-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1996-11-21 WO claimed
WO-1996019469-A1 DIARYL-2-(5H)-FURANONES AS COX-2 INHIBITORS MERCK FROSST CANADA INC. (CA) 1996-06-27 WO claimed
WO-1996010012-A1 NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-04-04 WO claimed
WO-1995026347-A1 THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1995-10-05 WO claimed
EP-0139917-A1 Pharmaceutical preparations, acylated hydrazine derivatives, methods for their preparation CIBA-GEIGY AG (CH) 1985-05-08 EP claimed